PDGFRB and melanoma: Sorafenib (RAF/KIT/VEGFR/PDGFR inhibitor) suppressed tumor growth in KIT-over-expressing melanoma models, and a complete but transient (five-month) response has been documented in a patient with anal mucosal melanoma harboring the exon 11 p.V560D alteration [51,52].